IMPACT COPD Study

A phase III, 52 week, randomized, double-blind, 3-arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF/UMEC/VI with the fixed dose dual combinations of FF/VI and UMEC/VI, all administered once-daily in the morning via a dry powder inhaler in subjects with chronic obstructive pulmonary disease.

Purpose: This study  is looking to enroll subjects who have COPD and have had an exacerbation of their COPD symptoms (flare up in, sick period) in the last 12 months. GlaxoSmithKline (GSK)

Sponsor: GlaxoSmithKline

Eligibility: You may be eligible if you are over 40 years of age and are a current or former smoker with a history of at least 10 pack years.

Principal Investigator: Cristine Berry, MD, MHS

 

Contact Information:

Osmara Y. Molina de Rodriguez, MS

Cell: (520) 891-6767 or Office: (520) 626-3910

Additional Information: ClinicalTrials.gov

 

Study Status: 
Completed